Introduction
Tocilizumab is an anti-interleukin-6 (IL-6) receptor monoclonal antibody
used in the management of rheumatoid arthritis.1 It is
effective at decreasing disease activity and improving function, and is
used as monotherapy or in combination with other disease-modifying
anti-rheumatic drugs.1 However, tocilizumab increases
the risk of serious infections,2,3 which can present
atypically for patients on tocilizumab – such as having mild clinical
features despite disseminated infection,4 or having
disproportionately low or normal C-reactive protein
(CRP).5 We present a previously unreported case ofStaphylococcus aureus subcapsular splenic abscess with associated
empyema in the setting of recent commencement of tocilizumab therapy.